doxazosin and Insulin Sensitivity
doxazosin has been researched along with Insulin Sensitivity in 18 studies
Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.
doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"We determined the effect of alpha-adrenergic blocking agent doxazosin on insulin resistance in 19 hypertensive patients (blood pressure [BP] >160/90 mmHg) with obesity (mean body mass index [BMI]: 26." | 9.10 | Effect of doxazosin on insulin resistance in hypertensive patients with obesity. ( Miyachi, Y; Ueshiba, H, 2003) |
"There are not studies about the utility of modified liberation doxazosin (MLD) in the combined treatment of the true resistant hypertension (TRH)." | 7.72 | [Effect of modified liberation doxazosin on blood pressure, insulin resistance, and catecholamine secretion in patients with true resistant hypertension]. ( Aliaga Martínez, L; Fernández-Torres, C; Jiménez-Alonso, J; Mediavilla García, JD; Sabio, JM, 2004) |
"The fibrinolytic and metabolic changes associated with doxazosin treatment were evaluated in 20 patients with mild to moderate hypertension." | 7.69 | Effect of doxazosin on fibrinolysis in hypertensive patients with and without insulin resistance. ( Huang, SH; Jeng, CY; Jeng, JR; Sheu, WH; Shieh, SM, 1996) |
"Insulin resistance (IR) in chronic renal failure (CRF) is well-known." | 6.70 | Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study. ( Akkaya, V; Celik, AV; Gürol, AO; Hursit, M; Karsidag, K; Kayacan, SM; Yazici, H; Yildiz, A, 2002) |
"Doxazosin treatment resulted in a dose-dependent reduction of basal insulin levels in group A to 16 +/- 3 microU/ml; p <0." | 5.30 | Effect of antihypertensive treatment with doxazosin on insulin sensitivity and fibrinolytic parameters. ( Beckmann, R; Binder, BR; Christ, G; Gabriel, H; Huber, K; Mundigler, G; Zehetgruber, M, 1998) |
"Treatment with doxazosin can lower blood pressure, reduce the levels of atherogenic lipids, increase the levels of cardioprotective lipids, reduce hyperinsulinaemia, insulin resistance and glucose intolerance, increase fibrinolysis, inhibit platelet aggregation, attenuate the adverse haemodynamic and haemostatic effects of smoking, and regress cardiac and smooth muscle hypertrophy." | 5.29 | Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient. ( Pool, JL, 1994) |
" The dose was titrated individually upwards from 1 mg until the diastolic blood pressure was below 90 mm Hg, side-effects precluded further dosage increase or the maximum daily dose of 16 mg was achieved." | 5.28 | Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients. ( Huupponen, R; Lehtonen, A; Vähätalo, M, 1992) |
"In the present study, 611 treated hypertensive patients with morning hypertension were randomized into either a doxazosin group, for whom a once-daily bedtime dose of doxazosin was added to the current medication regimen, or a control group, who continued their current medication." | 5.14 | Adrenergic blockade improved insulin resistance in patients with morning hypertension: the Japan Morning Surge-1 Study. ( Eguchi, K; Hoshide, S; Ishikawa, J; Ishikawa, S; Kabutoya, T; Kario, K; Matsui, Y; Pickering, TG; Shibasaki, S; Shimada, K, 2009) |
"We determined the effect of alpha-adrenergic blocking agent doxazosin on insulin resistance in 19 hypertensive patients (blood pressure [BP] >160/90 mmHg) with obesity (mean body mass index [BMI]: 26." | 5.10 | Effect of doxazosin on insulin resistance in hypertensive patients with obesity. ( Miyachi, Y; Ueshiba, H, 2003) |
"In a previous open study on the metabolic effects of doxazosin in patients with essential hypertension, subgroup analysis indicated that subjects with an accumulation of risk factors for coronary heart disease (high VLDL triglycerides, low HDL cholesterol and high fasting blood glucose) seemed to benefit most from the metabolic actions of doxazosin treatment." | 5.08 | Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men. Relationship to changes in skeletal muscle blood flow. ( Andersson, PE; Lithell, H, 1996) |
"Doxazosin (tonocardin) treatment was given for 11 weeks to 33 NIDDM patients with concomitant hypertension." | 5.08 | [Antihypertensive therapy with doxazosin in patients with non-insulin-dependent diabetes mellitus]. ( Lazebnik, LB; Melichenko, SB; Serebrov, AN, 1998) |
"There are not studies about the utility of modified liberation doxazosin (MLD) in the combined treatment of the true resistant hypertension (TRH)." | 3.72 | [Effect of modified liberation doxazosin on blood pressure, insulin resistance, and catecholamine secretion in patients with true resistant hypertension]. ( Aliaga Martínez, L; Fernández-Torres, C; Jiménez-Alonso, J; Mediavilla García, JD; Sabio, JM, 2004) |
"To examine the effect of the alpha 1-adrenoblocker tonocardin (doxazosin) on the course of arterial hypertension (AH) and on carbohydrate and lipid metabolism and insulin resistance in patients with type 2 diabetes mellitus (DM) concurrent with AH." | 3.71 | [Tonocardin in complex treatment of diabetes mellitus concurrent with hypertension]. ( Balabolkin, MI; Khasanova, ER; Kreminskaia, VM; Trukhina, TV, 2002) |
" With the monotherapy of essential hypertension concurrent with hypercholesterolemia with the alpha 1-adrenoblocker Doxazosin, in addition to the agent's high antihypertensive effects, the authors noted its favourable action on lipid spectral parameters and platelet functional activity." | 3.69 | [Hypertension, diabetes mellitus, atherosclerosis: clinical manifestations of metabolic syndrome X. Prospects of pharmacological treatment]. ( Ivleva, AIa; Kobalava, ZhD; Moiseev, VS, 1995) |
"The fibrinolytic and metabolic changes associated with doxazosin treatment were evaluated in 20 patients with mild to moderate hypertension." | 3.69 | Effect of doxazosin on fibrinolysis in hypertensive patients with and without insulin resistance. ( Huang, SH; Jeng, CY; Jeng, JR; Sheu, WH; Shieh, SM, 1996) |
"Insulin resistance was measured by homeostasis assessment index (HOMA)." | 2.73 | Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. ( Acikel, C; Caglar, K; Celik, T; Eyileten, T; Oguz, Y; Sonmez, A; Vural, A; Yavuz, I; Yenicesu, M; Yilmaz, MI, 2007) |
"Doxazosin has a neutral effect on both peripheral and hepatic insulin action, but improves endothelium-dependent vasodilation." | 2.71 | Effect of the alpha-adrenergic blocker, doxazosin, on endothelial function and insulin action. ( Atkinson, AB; Bassett, J; Bell, PM; Courtney, CH; Ennis, CN; McCance, DR; Sheridan, B, 2003) |
"Insulin resistance (IR) in chronic renal failure (CRF) is well-known." | 2.70 | Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study. ( Akkaya, V; Celik, AV; Gürol, AO; Hursit, M; Karsidag, K; Kayacan, SM; Yazici, H; Yildiz, A, 2002) |
"Doxazosin (2 to 4 mg) was administered alone or with other previously received antihypertensive drugs for 6 months." | 1.31 | Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients. ( Adachi, M; Hirano, T; Kashiwazaki, K; Yoshino, G, 2001) |
"Doxazosin treatment resulted in a dose-dependent reduction of basal insulin levels in group A to 16 +/- 3 microU/ml; p <0." | 1.30 | Effect of antihypertensive treatment with doxazosin on insulin sensitivity and fibrinolytic parameters. ( Beckmann, R; Binder, BR; Christ, G; Gabriel, H; Huber, K; Mundigler, G; Zehetgruber, M, 1998) |
"Treatment with doxazosin can lower blood pressure, reduce the levels of atherogenic lipids, increase the levels of cardioprotective lipids, reduce hyperinsulinaemia, insulin resistance and glucose intolerance, increase fibrinolysis, inhibit platelet aggregation, attenuate the adverse haemodynamic and haemostatic effects of smoking, and regress cardiac and smooth muscle hypertrophy." | 1.29 | Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient. ( Pool, JL, 1994) |
" The dose was titrated individually upwards from 1 mg until the diastolic blood pressure was below 90 mm Hg, side-effects precluded further dosage increase or the maximum daily dose of 16 mg was achieved." | 1.28 | Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients. ( Huupponen, R; Lehtonen, A; Vähätalo, M, 1992) |
Research
Studies (18)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 8 (44.44) | 18.2507 |
2000's | 9 (50.00) | 29.6817 |
2010's | 1 (5.56) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Shibasaki, S | 1 |
Eguchi, K | 1 |
Matsui, Y | 1 |
Ishikawa, J | 1 |
Hoshide, S | 1 |
Ishikawa, S | 1 |
Kabutoya, T | 1 |
Pickering, TG | 1 |
Shimada, K | 1 |
Kario, K | 1 |
Hamada, N | 1 |
Nishi, Y | 1 |
Tajiri, Y | 1 |
Setoyama, K | 1 |
Kamimura, R | 1 |
Miyahara, K | 1 |
Nuruki, N | 1 |
Hosoda, H | 1 |
Kangawa, K | 1 |
Kojima, M | 1 |
Mifune, H | 1 |
Yildiz, A | 1 |
Hursit, M | 1 |
Celik, AV | 1 |
Kayacan, SM | 1 |
Yazici, H | 1 |
Akkaya, V | 1 |
Gürol, AO | 1 |
Karsidag, K | 1 |
Balabolkin, MI | 1 |
Khasanova, ER | 1 |
Trukhina, TV | 1 |
Kreminskaia, VM | 1 |
Courtney, CH | 1 |
McCance, DR | 1 |
Atkinson, AB | 1 |
Bassett, J | 1 |
Ennis, CN | 1 |
Sheridan, B | 1 |
Bell, PM | 1 |
Ueshiba, H | 1 |
Miyachi, Y | 1 |
Mediavilla García, JD | 1 |
Sabio, JM | 1 |
Fernández-Torres, C | 1 |
Aliaga Martínez, L | 1 |
Jiménez-Alonso, J | 1 |
Yilmaz, MI | 1 |
Sonmez, A | 1 |
Caglar, K | 1 |
Celik, T | 1 |
Yenicesu, M | 1 |
Eyileten, T | 1 |
Acikel, C | 1 |
Oguz, Y | 1 |
Yavuz, I | 1 |
Vural, A | 1 |
Moiseev, VS | 1 |
Ivleva, AIa | 1 |
Kobalava, ZhD | 1 |
Pool, JL | 1 |
Andersson, PE | 1 |
Lithell, H | 1 |
Jeng, JR | 1 |
Sheu, WH | 1 |
Jeng, CY | 1 |
Huang, SH | 1 |
Shieh, SM | 1 |
Zehetgruber, M | 1 |
Christ, G | 1 |
Gabriel, H | 1 |
Mundigler, G | 1 |
Beckmann, R | 1 |
Binder, BR | 1 |
Huber, K | 1 |
Lazebnik, LB | 1 |
Melichenko, SB | 1 |
Serebrov, AN | 1 |
Takahashi, A | 1 |
Kushiro, T | 1 |
Kanmatsuse, K | 1 |
Hirano, T | 1 |
Yoshino, G | 1 |
Kashiwazaki, K | 1 |
Adachi, M | 1 |
Khan, MA | 1 |
Morgan, RJ | 1 |
Mikhailidis, DP | 1 |
Huupponen, R | 1 |
Lehtonen, A | 1 |
Vähätalo, M | 1 |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Valsartan Versus Amlodipine Effect on Left Ventricular Multidirectional Deformation and Adipocytokines Level in Hypertensive Patients: Speckle Tracking Echocardiography[NCT03990480] | Phase 4 | 230 participants (Actual) | Interventional | 2018-12-01 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trials
7 trials available for doxazosin and Insulin Sensitivity
Article | Year |
---|---|
Adrenergic blockade improved insulin resistance in patients with morning hypertension: the Japan Morning Surge-1 Study.
Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Antihypertensive Agents; Blood Pressure; Circ | 2009 |
Doxazosin, but not amlodipine decreases insulin resistance in patients with chronic renal failure: a prospective, randomized-controlled study.
Topics: Adult; Amlodipine; Antihypertensive Agents; Doxazosin; Female; Homeostasis; Humans; Insulin Resistan | 2002 |
Effect of the alpha-adrenergic blocker, doxazosin, on endothelial function and insulin action.
Topics: Acetylcholine; Adrenergic alpha-Antagonists; Adult; Aged; Blood Flow Velocity; Blood Glucose; Cross- | 2003 |
Effect of doxazosin on insulin resistance in hypertensive patients with obesity.
Topics: Adipose Tissue; Adrenergic alpha-Antagonists; Adult; Analysis of Variance; Doxazosin; Female; Humans | 2003 |
Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome.
Topics: Adiponectin; Adrenergic beta-Antagonists; Adult; Amlodipine; Angiotensin II Type 1 Receptor Blockers | 2007 |
Metabolic effects of doxazosin and enalapril in hypertriglyceridemic, hypertensive men. Relationship to changes in skeletal muscle blood flow.
Topics: Adult; Aged; Antihypertensive Agents; Body Mass Index; Double-Blind Method; Doxazosin; Enalapril; Fe | 1996 |
[Antihypertensive therapy with doxazosin in patients with non-insulin-dependent diabetes mellitus].
Topics: Aged; Antihypertensive Agents; Diabetes Mellitus, Type 2; Doxazosin; Female; Hemodynamics; Humans; H | 1998 |
Other Studies
11 other studies available for doxazosin and Insulin Sensitivity
Article | Year |
---|---|
Disrupted regulation of ghrelin production under antihypertensive treatment in spontaneously hypertensive rats.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic beta-1 Receptor Antagonists; Angiotensin II Type | 2012 |
[Tonocardin in complex treatment of diabetes mellitus concurrent with hypertension].
Topics: Adrenergic alpha-Antagonists; Adult; Anticholesteremic Agents; Antihypertensive Agents; Blood Glucos | 2002 |
[Effect of modified liberation doxazosin on blood pressure, insulin resistance, and catecholamine secretion in patients with true resistant hypertension].
Topics: Aldosterone; Antihypertensive Agents; Blood Pressure; Catecholamines; Doxazosin; Drug Resistance; Fe | 2004 |
[Hypertension, diabetes mellitus, atherosclerosis: clinical manifestations of metabolic syndrome X. Prospects of pharmacological treatment].
Topics: Anticholesteremic Agents; Arteriosclerosis; Diabetes Mellitus; Diabetes Mellitus, Type 2; Doxazosin; | 1995 |
Effects of doxazosin on coronary heart disease risk factors in the hypertensive patient.
Topics: Coronary Disease; Doxazosin; Humans; Hypertension; Hypertrophy, Left Ventricular; Insulin Resistance | 1994 |
Effect of doxazosin on fibrinolysis in hypertensive patients with and without insulin resistance.
Topics: Adrenergic alpha-Antagonists; Antihypertensive Agents; Blood Glucose; Case-Control Studies; Doxazosi | 1996 |
Effect of antihypertensive treatment with doxazosin on insulin sensitivity and fibrinolytic parameters.
Topics: Antihypertensive Agents; Dose-Response Relationship, Drug; Doxazosin; Fibrinolysis; Humans; Hyperten | 1998 |
[Effects of doxazosin and hydralazine on insulin sensitivity and sympathetic function in spontaneously hypertensive rat (SHR)].
Topics: Adrenergic alpha-Antagonists; Animals; Antihypertensive Agents; Doxazosin; Hydralazine; Hypertension | 1998 |
Doxazosin reduces prevalence of small dense low density lipoprotein and remnant-like particle cholesterol levels in nondiabetic and diabetic hypertensive patients.
Topics: Aged; Antihypertensive Agents; Apolipoproteins; Blood Glucose; Blood Pressure; C-Peptide; Cholestero | 2001 |
The choice of antihypertensive drugs in patients with erectile dysfunction.
Topics: Aged; Antihypertensive Agents; Diabetes Complications; Doxazosin; Erectile Dysfunction; Humans; Hype | 2002 |
Effect of doxazosin on insulin sensitivity in hypertensive non-insulin dependent diabetic patients.
Topics: Aged; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Doxazosin; Female; Heart Rate; Human | 1992 |